Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study
BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7423.1078 (Published 06 November 2003) Cite this as: BMJ 2003;327:1078Data supplement
- Acknowledgements
We thank the participants for their time; Pfizer, Roche, GlaxoSmithKline, and Zeneca for providing the drugs; Roche and GlaxoSmithKline for research grants; D Stürchler, J Handschin, M-L Mittelholzer (all formerly at Roche) for input in planning the study; G Miller, M Endrich (GlaxoSmithKline), M Philippi (Pfizer), and J P Fabre (Zeneca) for logistical support; P Culbert (GlaxoSmithKline, Canada), J-P Fabre (Zeneca, France), and C Taureau (Pfizer) for continuous monitoring of the quality and stability of the study drugs; Donna Merullo for assistance in the analysis of the profile of mood states data; Carmen Schwartz for translating the questionnaires from German to Hebrew; Roman Lässker for creating the ALLMALPRO (all-malaria-prophylaxis) web sites; Hans Peter Jauss for doing the figures; Maja Rentsch for data entry management of the quality of life and adverse events questionnaires; Nicola Funk for data entry of the profile of moods states; all involved in recruitment (Zürich: J Jücksel, F P Lücking, L Amsler, M Funk, M P Stürchler, and A Baños; Munich: M Santos; Basel: C H Hatz, U Legendre; Tel Hashomer: G Regev-Yochay; Frankfurt: S Franck); the medical residents at the Zürich satellite medical center on the Kenyan coast; and Albie deFrey, J Ferreira, and R Ferreirain Kruger Park for providing a back-up network of doctors in South Africa.
Related articles
- This Week In The BMJ Published: 06 November 2003; BMJ 327 doi:10.1136/bmj.327.7423.0-a
- Clinical Review Published: 12 June 2008; BMJ 336 doi:10.1136/bmj.a153
- Letter Published: 02 September 2004; BMJ 329 doi:10.1136/bmj.329.7465.573
- Editorial Published: 03 November 2015; BMJ 351 doi:10.1136/bmj.h5797
See more
- Bird flu: Person with rare strain in US sparks alarm about cow transmissionBMJ April 04, 2024, 385 q797; DOI: https://doi.org/10.1136/bmj.q797
- Antibiotic costs rise 1100% as big pharma exits NigeriaBMJ March 01, 2024, 384 q328; DOI: https://doi.org/10.1136/bmj.q328
- Measles: 500 cases are confirmed in England as clusters appear around the countryBMJ February 15, 2024, 384 q417; DOI: https://doi.org/10.1136/bmj.q417
- Alaskapox: First human death from zoonotic virus is announcedBMJ February 15, 2024, 384 q415; DOI: https://doi.org/10.1136/bmj.q415
- Diphtheria: WHO publishes first ever guidance following outbreaksBMJ February 14, 2024, 384 q407; DOI: https://doi.org/10.1136/bmj.q407
Cited by...
- Psychiatric side effects induced by chloroquine and hydroxychloroquine: a systematic review of case reports and population studies
- Imported Malaria in Countries where Malaria Is Not Endemic: a Comparison of Semi-immune and Nonimmune Travelers
- Neuropsychiatric Outcomes After Mefloquine Exposure Among U.S. Military Service Members
- Mefloquine for malarial prophylaxis in military personnel
- Psychiatric Side Effects of Mefloquine: Applications to Forensic Psychiatry
- Incidence of Malaria among Mosquito Collectors Conducting Human Landing Catches in Western Kenya
- Review: Malaria Chemoprophylaxis for Travelers to Latin America
- Cochrane Review highlights the need for more targeted research on the tolerability of malaria chemoprophylaxis in travellers
- Randomized, Double-Blind Study of the Safety, Tolerability, and Efficacy of Tafenoquine versus Mefloquine for Malaria Prophylaxis in Nonimmune Subjects
- Malaria Chemoprophylaxis: Strategies for Risk Groups
- Preventing malaria in travellers
- Management of Travelers with Fever and Exanthema, Notably Dengue and Chikungunya Infections
- Malaria Chemoprophylaxis: What Do the Travelers Choose, and How Does Pretravel Consultation Influence Their Final Decision
- EPIDEMIOLOGY OF MALARIA AMONG UNITED STATES GOVERNMENT PERSONNEL ASSIGNED TO DIPLOMATIC POSTS
- SPECTRUM OF DERMATOSES IN 165 TRAVELERS RETURNING FROM THE TROPICS WITH SKIN DISEASES
- DEATHS CAUSED BY MALARIA IN SWITZERLAND 1988-2002
- Cost considerations of malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis.
- ANTIBODY RESPONSES TO SEVERAL MALARIA PRE-ERYTHROCYTIC ANTIGENS AS A MARKER OF MALARIA EXPOSURE AMONG TRAVELERS
- Mefloquine use and hospitalizations among us service members, 2002-2004.
- "Serious" and "severe" adverse drug reactions need defining
- Preventing malaria in UK travellers
- Other articles noted: 14 Nov 2003 to 30 Jan 2004
- Adverse Events During Malaria Prophylaxis